» Articles » PMID: 35087588

Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention

Overview
Journal J Oncol
Specialty Oncology
Date 2022 Jan 28
PMID 35087588
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor immunotherapy brings substantial and long-term clinical benefits that can even cure tumors. However, the accumulation of evidence suggests that immunotherapy also induces severe and complex neurologic immune-related adverse events (ir-AEs) and even leads to immunotherapy-related death, which arouses the concern of clinicians. The timely and accurate identification of neurotoxicity helps clinicians detect and treat these complications early, thereby enhancing treatment efficiency and improving the prognosis of patients. At present, the mechanism of neurotoxicity caused by immunotherapy has not been completely elucidated. This paper mainly reviews the clinical features, pathogenesis, and therapeutic strategies of neurologic ir-AEs.

Citing Articles

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape.

Mulet-Margalef N, Linares J, Badia-Ramentol J, Jimeno M, Sanz Monte C, Manzano Mozo J Cancers (Basel). 2023; 15(4).

PMID: 36831367 PMC: 9954007. DOI: 10.3390/cancers15041022.

References
1.
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S . Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014; 16(4):589-93. PMC: 3956363. DOI: 10.1093/neuonc/nou001. View

2.
Magge R, DeAngelis L . The double-edged sword: Neurotoxicity of chemotherapy. Blood Rev. 2014; 29(2):93-100. PMC: 5944623. DOI: 10.1016/j.blre.2014.09.012. View

3.
Martinot M, Ahle G, Petrosyan I, Martinez C, Gorun D, Mohseni-Zadeh M . Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab. Emerg Infect Dis. 2018; 24(8):1594-1596. PMC: 6056118. DOI: 10.3201/eid2408.180460. View

4.
Buie L, Pecoraro J, Horvat T, Daley R . Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia. Ann Pharmacother. 2015; 49(9):1057-67. DOI: 10.1177/1060028015588555. View

5.
Siddiqi A . Rituximab as a possible cause of posterior reversible encephalopathy syndrome. Australas Med J. 2013; 4(9):513-5. PMC: 3562911. DOI: 10.4066/AMJ.2011.627. View